雄激素非依赖性前列腺癌的研究现状与进展  

Current status and research advances on androgen independent prostate cancer

作　　者：寿建忠[1] 李长岭[1] 

机构地区：[1]中国医学科学院中国协和医科大学肿瘤医院泌尿外科,北京100021

出　　处：《癌症进展》2005年第3期191-197,242,共8页Oncology Progress

摘　　要：前列腺癌是泌尿、男生殖系常见的恶性肿瘤之一,在我国发病率虽较低,但近年来呈显著增长的趋势。在我国,前列腺癌被临床上发现时大多已有转移,经雄激素祛除治疗大部分患者病情好转,但最终仍发展为雄激素非依赖性前列腺癌(AIPC)。目前临床上将雄激素非依赖性前列腺癌分为三类,其临床表现和预后不一。AIPC的发生、发展机制主要有两方面:①雄激素受体途径;②雄激素受体外的旁路途径,即不依赖于雄激素受体。事实上,大部分AIPC患者两条途径是共同存在、密不可分的。在治疗方面,最近两项大规模的Ⅲ期临床随机对照研究显示,以泰索帝为基础的化疗方案可明显延长AIPC的生存期。其预后与AIPC患者的生存状态、血红蛋白、乳酸脱氢酶等水平有关。Prostate cancer is one of the most common malignancy of genitourinary system.Although the incidence of prostate cancer is low in China,a remarkable in crease has been noted in recent years.Most patients have metastatic disease at diagnosis,which will eventually become androgen-independent prostafe cancer(AIPC) though it usually responds to androgen-ablation therapy initially.Androgen independent prostate cancer (AIPC) is divided into three subtypes with different clinical characters and outcome.The development of prostate cancer involves two pathways:Those involving the androgen receptor and those bypass the androgen receptor.These pathways are not mutually exclusive and frequently co-exist in androgen independent prostate cancer.Recently,the results of two large randomized phase Ⅲ clinical trial have revealed that docetaxel-based chemotherapy significantly prolonged the survival of AIPC and the outcome was associated with patient's performance status,level of hemoglobin and serum LDH.

关 键 词：前列腺癌 雄激素受体 治疗 预后 

分 类 号：R73[医药卫生—肿瘤]